API issues delay drug approval

Deficiencies at a manufacturing facility are holding up FDA approval of the antidepressant Trazodone. Labopharm, its maker, says its API manufacturer, Angelini, has said that the FDA concerns are "not critical." Article

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.